Benzinga··NaRein Therapeutics Raises $57.5M to Advance Pulmonary Fibrosis Drug Trial
Rein Therapeutics closed a $57.5 million public offering to fund its Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis, with runway extended through Q1 2028.
RNTXclinical trialpublic offering